Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
NORCROSS, Ga., March 23, 2017 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that trading will be halted in GALTW and GALTU at close of business on March 23, 2017 due to the expiration, on March 28, 2017, of certain publicly traded warrants that were issued in March 2012. The Company’s common stock, GALT, will not be affected and will continue to trade on the Nasdaq market. GALTU are units that were sold in March 2012 that consist of two shares of GALT common stock and one warrant. Unit holders had the right at any time to separate each GALTU unit into two shares of GALT common stock and one publicly traded warrant, and most unit holders exercised that right. GALTW are the free-standing warrants that were separated from the units. Unit holders who did not previously separate their units may now exchange each unit for two shares of GALT common stock.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Contact: Jack Callicutt, Chief Financial Officer (678) 620-3186 [email protected]
